ArticleJournal of inflammation research2025
TP-P1-Loaded Thermosensitive Hydrogel Attenuates Rheumatoid Arthritis in a Mouse Model via TLR4/NF-κB Pathway.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hydrogels loaded with different substances for treating heart failure: a promising therapy.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation, pain, and joint destruction, largely driven by inflammation and oxidative stress. This study explored the therapeutic potential of a thermosensitive hydrogel (TPTH) loaded with TP-P1, a derivative of triptolide, focusing on anti-inflammatory and antioxidant effects. Methods: A collagen-induced arthritis (CIA) model was established by dual immunization with type II collagen and Freund's adjuvant. Mice were randomized into control, model, dexamethasone (DEX), blank hydrogel, and TPTH groups. After 28 days of intra-articular treatment, arthritis severity was assessed by paw swelling, arthritis scores, and histopathology. Cytokines (IL-6, IL-1β, TNF-α) were measured by RT-qPCR and flow cytometry, oxidative stress markers (MDA, SOD, CAT, GSH) were determined, and TLR4/NF-κB expression was analyzed by Western blotting, immunohistochemistry, and RT-qPCR. Biosafety was evaluated via liver/kidney histology and plasma indices (ALT, AST, BUN, CRE). Results: TPTH treatment markedly alleviated arthritis symptoms, reducing paw swelling and scores (p < 0.0001). It downregulated inflammatory cytokines, improved antioxidant status (SOD, CAT, GSH) and decreased MDA. TPTH also suppressed TLR4 and NF-κB expression, indicating modulation of inflammatory signaling. Importantly, no obvious hepatic or renal toxicity was observed. Conclusion: TPTH significantly ameliorates inflammation and oxidative stress in CIA mice by modulating the TLR4/NF-κB pathway and shows promise as a safe and effective therapeutic strategy for RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.